Match!
E. Garret-Mayer
Johns Hopkins University
OncologyAdverse effectFamily medicineClinical trialMedicine
13Publications
4H-index
43Citations
What is this?
Publications 16
Newest
#1E. Garret-Mayer (American Society of Clinical Oncology)H-Index: 4
Source
#1Ashley M. Hopkins (Flinders University)H-Index: 6
#2Ganessan Kichenadasse (Flinders University)H-Index: 15
Last. Michael J. Sorich (Flinders University)H-Index: 24
view all 6 authors...
Purpose: Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC), however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in advanced NSCLC patients treated with ICIs. Experimental Design: A pre-treatment prognostic model was developed and validated using clinicopathological data. Development data consisted of advanced NSCLC patients treated ...
Source
#1E. Garret-Mayer (American Society of Clinical Oncology)H-Index: 4
#2Melinda Kaltenbaugh (American Society of Clinical Oncology)
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 7 authors...
PURPOSECompany-reported payments from the Open Payments database (OP) have been compared with self-disclosed financial relationships made by physician authors. Discrepancies have been viewed as und...
Source
#1Tareq Al BaghdadiH-Index: 2
#2Susan Halabi (Duke University)H-Index: 60
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 14 authors...
PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that ...
Source
#1Kathryn F. MilehamH-Index: 3
#2Caroline Schenkel (American Society of Clinical Oncology)H-Index: 1
Last. Julie Marie Vose (UNMC: University of Nebraska Medical Center)H-Index: 84
view all 11 authors...
PURPOSE:Investigators often send reports to sponsors that incorrectly categorize adverse event (AE)s as serious or attribute AEs to investigational drugs. Such errors can contribute to high volumes...
Source
#1Aidan Gilbert (UAB: University of Alabama at Birmingham)
#2Pravinkumar G. Kandhare (UAB: University of Alabama at Birmingham)
Last. Gabrielle B. Rocque (UAB: University of Alabama at Birmingham)H-Index: 11
view all 12 authors...
317Background: Electronic health record (EHR) databases are a promising platform for clinical research using real-world data. However, information on potential limitations of these data sources is ...
Source
#1Aidan Gilbert (UAB: University of Alabama at Birmingham)
#2Courtney P. Williams (UAB: University of Alabama at Birmingham)H-Index: 7
Last. Gabrielle B. Rocque (UAB: University of Alabama at Birmingham)H-Index: 11
view all 13 authors...
316Background: Optimal treatment sequencing (i.e., the order in which drugs are given) for metastatic breast cancer (MBC) is unknown. We aimed to develop an approach to visualize treatment patterns...
Source
#1N. I. Cherny (Shaare Zedek Medical Center)H-Index: 5
#2Elisabeth G.E. de Vries (UG: University of Groningen)H-Index: 86
Last. Richard L. Schilsky (American Society of Clinical Oncology)H-Index: 66
view all 19 authors...
PURPOSETo better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) and the ASCO Value Framework Net Health Benefit score version ...
9 CitationsSource
#1Brian P. Hobbs (Cleveland Clinic)H-Index: 2
#2Pedro C. Barata (Tulane University)H-Index: 7
Last. Gary L. Rosner (Johns Hopkins University)H-Index: 18
view all 19 authors...
Source
#1Pam K. MangatH-Index: 2
#2Susan HalabiH-Index: 60
Last. Richard L. SchilskyH-Index: 66
view all 13 authors...
PurposeCase reports and small prospective trials suggest that administering targeted therapies to patients with advanced cancer and an identified genomic target may be associated with clinical benefit. The Targeted Agent and Profiling Utilization Registry (TAPUR) study, a phase II prospective, nonrandomized, multibasket pragmatic clinical trial, aims to identify signals of drug activity when US Food and Drug Administration–approved drugs are matched to prespecified genomic targets in patients wi...
4 CitationsSource
12